Cargando…

Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli

Minimal inhibitory concentration-based pharmacokinetic/pharmacodynamic (PK/PD) indices are commonly applied to antibiotic dosing optimisation, but their informative value is limited, as they do not account for bacterial growth dynamics over time. We aimed to comprehensively characterise the exposure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seeger, Johanna, Guenther, Sebastian, Schaufler, Katharina, Heiden, Stefan E., Michelet, Robin, Kloft, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224043/ https://www.ncbi.nlm.nih.gov/pubmed/34063980 http://dx.doi.org/10.3390/antibiotics10060615

Ejemplares similares

A Model-Based Pharmacokinetic/Pharmacodynamic Analysis of the Combination of Amoxicillin and Monophosphoryl Lipid A Against S. pneumoniae in Mice
por: Franck, Sebastian, et al.
Publicado: (2021)

Clinical Impact of Fluoroquinolone-Resistant Escherichia coli in the Fecal Flora of Hematological Patients with Neutropenia and Levofloxacin Prophylaxis
por: Chong, Yong, et al.
Publicado: (2014)

Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin
por: Busse, David, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Integration and Modeling of Enrofloxacin in Swine for Escherichia coli
por: Wang, Jianyi, et al.
Publicado: (2016)

Pharmacokinetic–Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers
por: Sang, KaNa, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization
por: Cao, G, et al.
Publicado: (2013)

Biotransformation of the Fluoroquinolone, Levofloxacin, by the White-Rot Fungus Coriolopsis gallica
por: Ben Ayed, Amal, et al.
Publicado: (2022)

Fluoroquinolone-resistant Escherichia coli, Indonesia
por: Kuntaman, Kuntaman, et al.
Publicado: (2005)

Fluoroquinolone Can Be an Effective Treatment Option for Acute Pyelonephritis When the Minimum Inhibitory Concentration of Levofloxacin for the Causative Escherichia coli Is ≤16 mg/L
por: Kim, Yeonjae, et al.
Publicado: (2021)

Microbiome diversity in carriers of fluoroquinolone resistant Escherichia coli
por: Liss, Michael A., et al.
Publicado: (2019)

Multidrug-Resistant High-Risk Escherichia coli and Klebsiella pneumoniae Clonal Lineages Occur in Black-Headed Gulls from Two Conservation Islands in Germany
por: Brendecke, Jana, et al.
Publicado: (2022)

Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism
por: Schulz, Josefine, et al.
Publicado: (2022)

In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens
por: Xiao, Xia, et al.
Publicado: (2018)

Extended-Spectrum ß-Lactamase-Producing Escherichia coli in Conventional and Organic Pig Fattening Farms
por: Meissner, Katharina, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducks
por: Yu, Yang, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling
por: Liu, Xuesong, et al.
Publicado: (2021)

Rapid evolution of fluoroquinolone-resistant Escherichia coli in Nigeria is temporally associated with fluoroquinolone use
por: Lamikanra, Adebayo, et al.
Publicado: (2011)

ESBL-plasmids carrying toxin-antitoxin systems can be “cured” of wild-type Escherichia coli using a heat technique
por: Schaufler, Katharina, et al.
Publicado: (2013)

Resistance pattern of Escherichia coli to levofloxacin in Iran: a narrative review
por: Hassanshahi, Gholamhossein, et al.
Publicado: (2020)

SOS Response Induces Persistence to Fluoroquinolones in Escherichia coli
por: Dörr, Tobias, et al.
Publicado: (2009)

Distribution of fluoroquinolones in the two aqueous compartments of Escherichia coli
por: Pandeya, Ankit, et al.
Publicado: (2020)

High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli
por: Rattanaumpawan, Pinyo, et al.
Publicado: (2017)

Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models
por: van der Meijden, Aart, et al.
Publicado: (2023)

Effects of the Fluoroquinolones Moxifloxacin and Levofloxacin on the QT Subintervals: Sex Differences in Ventricular Repolarization
por: Täubel, Jӧrg, et al.
Publicado: (2019)

Highly Virulent and Multidrug-Resistant Escherichia coli Sequence Type 58 from a Sausage in Germany
por: Eger, Elias, et al.
Publicado: (2022)

Biofilm and fluoroquinolone resistance of canine Escherichia coli uropathogenic isolates
por: Oliveira, Manuela, et al.
Publicado: (2014)

Fluoroquinolone consumption and Escherichia coli resistance in Japan: an ecological study
por: Terahara, Fumitaka, et al.
Publicado: (2019)

Analysis of fluoroquinolones in dusts from intensive livestock farming and the co-occurrence of fluoroquinolone-resistant Escherichia coli
por: Schulz, Jochen, et al.
Publicado: (2019)

Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
por: Al-Shaer, Mohammad H., et al.
Publicado: (2019)

Key Factors in Effective Patient-Tailored Dosing of Fluoroquinolones in Urological Infections: Interindividual Pharmacokinetic and Pharmacodynamic Variability
por: Estradé, Oskar, et al.
Publicado: (2022)

Pleiotropic Effects of Levofloxacin, Fluoroquinolone Antibiotics, against Influenza Virus-Induced Lung Injury
por: Enoki, Yuki, et al.
Publicado: (2015)

Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?
por: Karampela, Irene, et al.
Publicado: (2020)

Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
por: Michelet, Robin, et al.
Publicado: (2023)

Broiler Chickens as Source of Human Fluoroquinolone-Resistant Escherichia coli, Iceland
por: Thorsteinsdottir, Thorunn R., et al.
Publicado: (2010)

Fluoroquinolone-resistant Escherichia coli Carriage in Long-Term Care Facility
por: Maslow, Joel N., et al.
Publicado: (2005)

Effects of disruption of heat shock genes on susceptibility of Escherichia coli to fluoroquinolones
por: Yamaguchi, Yuko, et al.
Publicado: (2003)

Quinolones and fluoroquinolones are useless to counter uropathogenic Escherichia coli infections [Letter]
por: Singh, Bhoj R
Publicado: (2019)

Prevalence and Molecular Characterization of Fluoroquinolone-Resistant Escherichia coli in Healthy Children
por: Zhao, Qiang, et al.
Publicado: (2021)

Efficacy of Cefquinome against Escherichia coli Environmental Mastitis Assessed by Pharmacokinetic and Pharmacodynamic Integration in Lactating Mouse Model
por: Yu, Yang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8nnhlqdmf6afk6n10cl9adlmik